A Randomized Study of Haploidentical Lymphocytes With Nivolumab and Intermediate Dose Cytarabine Versus Nivolumab and Intermediate Dose Cytarabine as Consolidation Treatment in Older Adults With Acute Myeloid Leukemia
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Cytarabine (Primary) ; Nivolumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 Apr 2019 Status changed from recruiting to discontinued.
- 29 Dec 2017 New trial record